iBio is a clinical stage biotech developing AI designed antibody drugs for obesity and related heart and lung diseases. It last closed at $0.80 on Nov 20, down 0.11% on the day. The next earnings report for IBIO is expected around Tue, Feb 9, 2027, after the close. For the quarter ended Sep 2026, IBIO reported EPS of -$0.05 on revenue of $1.1M, with revenue up 975.0% from a year ago. Over its last 8 reports the stock moved an average of 4.2% the session after earnings. Over the last 12 months IBIO insiders bought $98K of stock on the open market and sold $0, according to SEC Form 4 filings.
AI Auto Pilots
Is IBIO in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold IBIO.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on IBIOStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
IBIO · as of the Nov 20 close · updated each morning
Downtrend
The stock sits between its 20 and 50 day averages. It is 98% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 48). The nearest support is the Pivot at $0.80, and the nearest resistance the swing high (Nov 11) at $0.83.
Short trendBearish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityNormal, 9.5%/day
Key levels
$3.8252 week high+377.5%
$1.58200 day average+97.5%
$1.17100 day average+46.2%
$0.9350 day average+16.3%
$0.83Pivot R1+3.7%
$0.83Swing high (Nov 11)+3.7%
$0.80Pivot+0.0%
$0.80Last close
$0.7820 day average−2.5%
$0.77Pivot S1−3.7%
$0.73Swing low (Oct 14)−8.8%
$0.6852 week low−15.0%
Indicators
RSI (14)
47.80
Middle of its range
Neutral
MACD
-0.03
Above its signal line
Bullish
Stochastic
73.2
Middle of its range
Neutral
ADX (14)
20.4
Weak trend
Williams %R
-35.2
Oversold below −80, overbought above −20
Neutral
CCI (20)
48.5
Oversold below −100, overbought above 100
Neutral
Rate of change
+8.3%
Change over 10 sessions
Bullish
ATR (14)
$0.08
Typical daily range, 9.5% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 28.3%/day
Key levels
$3.8252 week high+377.5%
$1.58200 day average+97.5%
$1.17100 day average+46.2%
$0.9350 day average+16.3%
$0.83Pivot R1+3.7%
$0.83Swing high (Nov 11)+3.7%
$0.80Pivot+0.0%
$0.80Last close
$0.7820 day average−2.5%
$0.77Pivot S1−3.7%
$0.73Swing low (Oct 14)−8.8%
$0.6852 week low−15.0%
Indicators
RSI (14)
32.78
Weak, oversold below 30
Neutral
MACD
-0.25
Below its signal line
Bearish
Stochastic
8.9
Near the bottom of its range
Oversold
ADX (14)
18.9
No clear trend
Williams %R
-84.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-100.0
Oversold below −100, overbought above 100
Neutral
Rate of change
−33.6%
Change over 10 sessions
Bearish
ATR (14)
$0.23
Typical daily range, 28.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for IBIO
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how IBIO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow IBIO usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for IBIOHow many large options trades hit IBIO, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in IBIO in the last 90 days.
From SEC Form 4 filings by IBIO's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IBIO is in one of them and how their past IBIO trades turned out.
iBio is a biotechnology company that uses artificial intelligence to design antibody drugs. Its work focuses on obesity and related heart and lung conditions, including pulmonary hypertension linked to heart failure. Its lead candidate, IBIO-600, is in a Phase 1 clinical trial, and other candidates are in earlier preclinical development. No products are approved yet, so its intended customers are patients with these conditions and the clinicians who treat them. The company is based in New York and conducts its research at a laboratory in San Diego.